FDA Denial Of Mucinex Petition Stops Reckitt's Bid To Delay Generics
This article was originally published in The Tan Sheet
FDA stymies Reckitt Benckiser's attempt to delay private label competition for Mucinex OTC cough products by rejecting the firm's request to redefine bioequivalence standards for guaifenesin generics
You may also be interested in...
Quality control problems for Johnson & Johnson's McNeil Consumer Healthcare business and the regulatory and congressional scrutiny that followed dominated the attention of drug and dietary supplement industry stakeholders in 2010.
An appeals court decision against Perrigo further delays the private labeler's plans to launch a Mucinex equivalent, leaving the Reckitt Benckiser decongestant still unchallenged by generic competition
Reckitt Benckiser looks to continue feeding organic growth through innovative product launches, as discussion of the company's acquisition search has quieted in recent months